FDA
-
-
-
-
-
-
-
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
-
-
-
-
-
-
-
Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis® LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting
-
-
-
-
-
-
-
Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)
-
-
-
-
-
-
-
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
-
-
-
-
-
-
-
Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results
-
-
-
-
-
-
-
Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook
-
-
-
-
-
-
-
Median Technologies Reports Full-year 2022 Results and Business Indicators for the First Quarter Of 2023
-
325,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

